Girod A - Search Results

1

In vitro selection of viral vectors with modified tropism: the adeno-associated virus display.

Perabo L, Büning H, Kofler DM, Ried MU, Girod A, Wendtner CM, Enssle J, Hallek M. Perabo L, et al. Among authors: girod a. Mol Ther. 2003 Jul;8(1):151-7. doi: 10.1016/s1525-0016(03)00123-0. Mol Ther. 2003. PMID: 12842438 Free article.

2

Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors.

Ried MU, Girod A, Leike K, Büning H, Hallek M. Ried MU, et al. Among authors: girod a. J Virol. 2002 May;76(9):4559-66. doi: 10.1128/jvi.76.9.4559-4566.2002. J Virol. 2002. PMID: 11932421 Free PMC article.

3

The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity.

Girod A, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M. Girod A, et al. J Gen Virol. 2002 May;83(Pt 5):973-978. doi: 10.1099/0022-1317-83-5-973. J Gen Virol. 2002. PMID: 11961250

4

Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid.

Huttner NA, Girod A, Schnittger S, Schoch C, Hallek M, Büning H. Huttner NA, et al. Among authors: girod a. J Gene Med. 2003 Feb;5(2):120-9. doi: 10.1002/jgm.324. J Gene Med. 2003. PMID: 12539150

5

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.

Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, Hallek M. Huttner NA, et al. Among authors: girod a. Gene Ther. 2003 Dec;10(26):2139-47. doi: 10.1038/sj.gt.3302123. Gene Ther. 2003. PMID: 14625569

6

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M. Girod A, et al. Nat Med. 1999 Sep;5(9):1052-6. doi: 10.1038/12491. Nat Med. 1999. PMID: 10470084

7

Recombinant adeno-associated virus vectors.

Hallek M, Girod A, Braun-Falco M, Wendtner CM, Bogedain C, Hörer M. Hallek M, et al. Among authors: girod a. IDrugs. 1998 Sep;1(5):561-73. IDrugs. 1998. PMID: 18465596

8

Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.

Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH. Nicklin SA, et al. Among authors: girod a. Mol Ther. 2001 Sep;4(3):174-81. doi: 10.1006/mthe.2001.0424. Mol Ther. 2001. PMID: 11545607 Free article.

9

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Wobus CE, Hügle-Dörr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Wobus CE, et al. Among authors: girod a. J Virol. 2000 Oct;74(19):9281-93. doi: 10.1128/jvi.74.19.9281-9293.2000. J Virol. 2000. PMID: 10982375 Free PMC article.

10

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M. Girod A, et al. Nat Med. 1999 Dec;5(12):1438. doi: 10.1038/71021. Nat Med. 1999. PMID: 10581091 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters